Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Other equities analysts also recently issued reports about the company. Morgan Stanley boosted their price objective on Natera from $125.00 to $132.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 13th. BTIG Research upped their price objective on shares of Natera from $125.00 to $135.00 and gave the stock a "buy" rating in a report on Friday, August 9th. UBS Group lowered their target price on shares of Natera from $160.00 to $145.00 and set a "buy" rating on the stock in a research note on Friday, August 9th. Leerink Partners upped their price target on shares of Natera from $140.00 to $150.00 and gave the stock an "outperform" rating in a research note on Thursday, October 17th. Finally, TD Cowen raised their price objective on shares of Natera from $137.00 to $145.00 and gave the company a "buy" rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $124.44.
Check Out Our Latest Report on Natera
Shares of NTRA opened at $119.17 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The company has a market cap of $14.74 billion, a P/E ratio of -48.64 and a beta of 1.53. Natera has a 12 month low of $36.90 and a 12 month high of $133.54. The stock has a fifty day moving average price of $123.37 and a 200 day moving average price of $111.09.
Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.39. The business had revenue of $413.35 million for the quarter, compared to analysts' expectations of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company's revenue for the quarter was up 58.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.97) EPS. On average, research analysts forecast that Natera will post -1.96 earnings per share for the current year.
In other news, insider Daniel Rabinowitz sold 1,057 shares of Natera stock in a transaction on Monday, July 29th. The stock was sold at an average price of $102.77, for a total transaction of $108,627.89. Following the transaction, the insider now owns 206,400 shares in the company, valued at approximately $21,211,728. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, insider Daniel Rabinowitz sold 1,057 shares of the firm's stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $102.77, for a total transaction of $108,627.89. Following the transaction, the insider now owns 206,400 shares of the company's stock, valued at approximately $21,211,728. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Burkes Brophy sold 1,238 shares of Natera stock in a transaction on Monday, July 29th. The shares were sold at an average price of $102.77, for a total transaction of $127,229.26. Following the completion of the sale, the chief financial officer now directly owns 73,821 shares of the company's stock, valued at approximately $7,586,584.17. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 49,458 shares of company stock valued at $5,924,920 in the last three months. 7.60% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in NTRA. Vanguard Group Inc. boosted its position in Natera by 0.7% during the first quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company's stock worth $1,010,152,000 after purchasing an additional 72,848 shares during the period. Farallon Capital Management LLC lifted its stake in shares of Natera by 13.6% in the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company's stock worth $483,034,000 after buying an additional 532,874 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Natera by 6.6% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company's stock worth $259,634,000 after buying an additional 148,917 shares during the last quarter. Duquesne Family Office LLC boosted its holdings in shares of Natera by 2.4% during the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company's stock worth $213,860,000 after buying an additional 45,500 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its stake in Natera by 25.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company's stock valued at $156,092,000 after buying an additional 246,246 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.